General Information

We are a clinical-stage biotechnology company developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Our initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2, which play key roles in regulating fibrosis. We believe our product candidates are distinct from the current generation of antifibrotic agents and have the potential to significantly improve patients’ clinical outcomes and enhance their quality of life.

Our lead product candidate, GB0139, is an orally inhaled inhibitor of galectin-3. We are developing GB0139 for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung that affects approximately 100,000 people in the United States.  We have conducted a Phase 2a study in 24 IPF patients, and we have initiated a potentially registrational, randomized Phase 2b trial in 450 IPF patients. We expect topline results from this trial to be available in 2022. (*Net loss figure is for the year ended 12/31/19, from the prospectus.)

Industry: Pharmaceuticals
Founded: 2011
Contact Information
Address Ole Maaloes Vej 3 DK-2200 Copenhagen N Denmark
Phone Number (+45) 70 70 52 10
Web Address
View Prospectus: Galecto
Financial Information
Market Cap $368.85mil
Revenues $0 mil (last 12 months)
Net Income $-36.5 mil (last 12 months)
IPO Profile
Symbol GLTO
Exchange NASDAQ
Shares (millions): 5.7
Price range $15.00 - $15.00
Est. $ Volume $85.5 mil
Manager / Joint Managers BofA Securities/ SVB Leerink/ Credit Suisse
CO-Managers Kempen & Co.
Expected To Trade: 10/29/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change